HD201与参照曲妥珠单抗在新辅助治疗ERBB2阳性乳腺癌患者中的疗效比较:一项多中心3期随机临床试验
TROIKA试验纳入502例ERBB2阳性早期乳腺癌女性,随机接受HD201或参照曲妥珠单抗新辅助治疗8周期。主要终点tpCR率HD201组45% vs 参照组48.7%,差异-3.8%(95%CI -12.8%至5.4%),落在预设等效界值内,两组安全性相似。
要点
- HD201组tpCR率45%,参照曲妥珠单抗组48.7%,差异-3.8%(95%CI -12.8%至5.4%),落在±15%等效界值内。
- 两组tpCR率比值为0.92(95%CI 0.76至1.12)。
- 总共433例(86.1%)发生2232例次治疗中出现的不良事件,HD201组220例(88.0%) vs 参照组213例(84.5%)。
核心结论
- HD201在tpCR终点上显示与参照曲妥珠单抗等效,安全性特征相似。
研究设计与样本
- 多中心3期随机临床试验(TROIKA),纳入502例ERBB2阳性早期乳腺癌女性,随机接受HD201或参照曲妥珠单抗。
- 试验在12个国家的70个中心开展,随机化按肿瘤激素受体状态、临床分期和招募地理区域分层。
- 分析于2021年2月12日完成,中位随访31个月(IQR 28-33个月)。
- 新辅助治疗8周期HD201或参照曲妥珠单抗,同时联合4周期多西他赛后序贯4周期表柔比星和环磷酰胺。
- 手术后辅助治疗10周期HD201或参照曲妥珠单抗。
主要发现
- 符合方案集474例(94.2%)纳入分析。
- 基线特征两组均衡,195例肿瘤(38.8%)激素受体阴性,213例(42.4%)临床III期。
- tpCR率HD201组45% vs 参照曲妥珠单抗组48.7%,差异-3.8%(95%CI -12.8%至5.4%),未达统计学显著,落在预设等效界值内。
- 两组tpCR率比值0.92(95%CI 0.76至1.12)。
- 433例(86.1%)发生2232例次治疗中出现的不良事件,HD201组220例(88.0%) vs 参照组213例(84.5%)。
关键数值与推荐
- 主要终点为tpCR,若符合方案集中两组tpCR绝对差异的95%CI在±15%界值内则判定等效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The drug HD201 is a biosimilar candidate for breast cancer treatment as the reference trastuzumab. OBJECTIVE: To compare the efficacy of HD201 with referent trastuzumab. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial (TROIKA) included 502 women with ERBB2-positive early breast cancer treated with either HD201 or referent trastuzumab. It was conducted across 70 centers in 12 countries, including Western and Eastern Europe and Asian countries. Randomization was stratified by tumor hormone receptor status, clinical stage, and geographic region of recruitment. This analysis was conducted on February 12, 2021, after the completion of the adjuvant phase at a median of 31 months (IQR, 28-33 months) of follow-up. INTERVENTIONS: Patients with ERBB2-positive early breast cancer were randomly assigned to receive HD201 or referent trastuzumab in the neoadjuvant setting for 8 cycles, concurrently with 4 cycles of docetaxel, which was followed by 4 cycles of epirubicin and cyclophosphamide. Patients then underwent surgery, which was followed by treatment with 10 cycles of adjuvant HD201 or referent trastuzumab. MAIN OUTCOME AND MEASURES: The primary end point was the total pathological complete response (tpCR) assessed after neoadjuvant treatment. Equivalence was concluded if the 95% CI of the absolute difference in tpCR between arms in the per-protocol set was within the margin of more or less than 15%. Other objectives included the breast pathological complete response, overall response, event-free and overall survival, safety, pharmacokinetics, and immunogenicity. RESULTS: A total of 502 female patients (mean [range] age, 53 [26-82] years) were randomized to receive either HD201 or referent trastuzumab, and 474 (94.2%) were eligible for inclusion in the per-protocol set. The baseline characteristics were well balanced between the 2 arms; 195 tumors (38.8%) were hormone receptor-negative , and 213 patients (42.4%) had clinical stage III disease. The tpCR rates were 45% and 48.7% for HD201 and referent trastuzumab, respectively. The difference between the 2 groups was not significant at -3.8% (95% CI, -12.8% to 5.4%) and fell within the predefined equivalence margins. The ratio of the tpCR rates between the 2 arms was 0.92 (95% CI, 0.76 to 1.12). A total of 433 patients (86.1%) presented with 2232 treatment-emergent adverse events of special interest for trastuzumab during the entire treatment period, with 220 (88.0%) and 213 (84.5%) patients in the HD201 and referent trastuzumab groups, respectively. CONCLUSIONS AND RELEVANCE: The results of this randomized clinical trial found that HD201 demonstrated equivalence to referent trastuzumab in terms of efficacy for the end point of tpCR, with a similar safety profile. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03013504.
引用
- Pivot X, Georgievich MA, Shamrai V, et al. Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022. PMID: 35238873. doi:10.1001/jamaoncol.2021.8171
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。